$0.661
+0.033 (+4.92%)At close
- High
- 0.700
- Open
- 0.635
- VWAP
- 0.66
- Vol
- 42.43K
- Mkt Cap
- 12.02M
- Low
- 0.620
- Amount
- 28.02K
- EV/EBITDA, TTM
- -0.00
RedHill Biopharma Ltd is an Israel-based specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn's disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting.
AI analysis of Redhill Biopharma Ltd (RDHL)
holdRedhill Biopharma Ltd (RDHL) is currently not a strong buy due to its high RSI of 72.825, indicating overbought conditions, and a forward P/E ratio of 1428.57, which suggests that the stock is highly overvalued compared to its earnings potential. While there is potential for growth due to the recent FDA designations, the company has a significant risk with a current ratio of 0.54, indicating potential liquidity issues.
Analyst Ratings (4)
Valuation Metrics
Events Timeline
News
2.007-28PRnewswireEbola Cases Surge, Urgent Need for Treatment Evaluation
8.506-22PRnewswireRedHill Biopharma Closes Private Placement Raising $6 Million
8.506-22NewsfilterRedHill Biopharma Completes Private Placement Financing
8.506-18seekingalphaRedHill Biopharma Enters ADS Purchase Agreement
- 8.506-18PRnewswire
RedHill Biopharma Completes Private Placement Financing
RDHL FAQ — answered by Alphio AI
RedHill Biopharma Ltd is an Israel-based specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn's disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Redhill Biopharma Ltd (RDHL) is currently not a strong buy due to its high RSI of 72.825, indicating overbought conditions, and a forward P/E ratio of 1428.57, which suggests that the stock is highly overvalued compared to its earnings potential. While there is potential for growth due to the recent FDA designations, the company has a significant risk with a current ratio of 0.54, indicating potential liquidity issues.
4 analysts cover RDHL: 4 rate it Buy, 0 Hold and 0 Sell.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.